By Nathalie Moll, Director General, European Federation of Pharmaceutical Industries and Associations (EFPIA)
At EFPIA, we work across a wide spectrum of topics from prevention and awareness, through research and development (R&D), regulatory and Health Technology Assessment (HTA) processes, managing relationships, to developing healthcare service design and outcomes measurement. Each one has a direct impact on the lives of patients, their families and carers across Europe.
Actively listening to patient experiences and patient challenges, and exchanging insights, must shape how we develop our policy, processes and practice. It is only through open and transparent dialogue between patients, industry and other key stakeholders that we can ensure the patient perspective becomes an integral part of how medicines are researched, developed and delivered to patients.
This is why patient engagement is at the forefront of EFPIA’s work and why I am very proud that EFPIA is part of the groundbreaking IMI PARADIGM programme. One of PARADIGM’s key strengths is its collaborative, inclusive approach to bringing together a wide range of stakeholders, including industry, the academic community, regulators and, most crucially, patients to design and build tools and share information to support the biomedical research community in meaningfully engaging with patients throughout the R&D process.
PARADIGM has a specific focus on making patient engagement happen across three main moments of medicines development where patient input is not yet systematically sought. These are research and priority setting, the design of clinical trials, and early dialogue with regulators and HTA bodies. In PARADIGM we share our knowledge and experience to develop new tools and processes and a sustainability roadmap to improve patient engagement practices. In addition, we also aim to make a strong case for patient engagement by capturing and measuring the tangible benefits it brings.
PARADIGM’s ambition goes beyond providing practical tools and a measurement framework. This project is set out to bring real cultural change across the board, making collaboration an integral part of the European research culture, challenging the status quo and providing a safe space to discuss how to do things differently.
Cultural and practical change both take time and EFPIA and its PARADIGM partners are committed to making change happen to deliver better care for patients.
Nathalie Moll, Director General, European Federation of Pharmaceutical Industries and Associations (EFPIA)
Nathalie Moll joined the European Federation of Pharmaceutical Industries and Associations (EFPIA) as Director General in April 2017.
EFPIA represents the pharmaceutical industry operating in Europe. Together with its direct membership 40 leading pharmaceutical companies, 33 national associations representing over 1,900 companies and in collaboration with health and research players, EFPIA’s mission is to create an environment that enables our members to innovate, discover, develop and deliver new therapies and vaccines for people across Europe, as well as contribute to the European economy.
Prior to joining EFPIA, between 2010 and 2017, Nathalie was the Secretary-General of EuropaBio ranked as the most effective European Trade Association in Brussels in 2013. She spent over 20 years working for the biotech industry at EU and national level in associations and corporate positions and held the position of Chair and Vice Chair of the International Council of Biotech Associations (ICBA).
In 2013, Nathalie won the Technovisionaries Women Innovation Award organised by Women & Technologies® while in 2009, Nathalie and the Green Biotech Team of EuropaBio were presented with the Leadership and Excellence in Advancing Ag-Biotech and Food Issues Award. Nathalie was also named one of the 15 leading women in biotech in Europe in 2017.
Nathalie holds an Honours Degree in Biochemistry and Biotechnology from St Andrews University, Scotland.